{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:27:03Z","timestamp":1789540023652,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,10,26]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Coprescribing of benzodiazepines\/Z-drugs (BZDs) and opioids is a drug-use pattern of considerable concern due to risk of adverse events. The objective of this study is to estimate the effect of concurrent use of BZDs on the risk of hospitalisations\/emergency department (ED) visits and deaths among opioid users.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, setting and participants<\/jats:title>\n                  <jats:p>We conducted a population-based case cross-over study during 2016\u20132018 involving Albertans 18 years of age and over who received opioids. From this group, we identified 1\u2009056\u2009773 people who were hospitalised or visited the ED, and 31\u2009998 who died.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Concurrent use of opioids and BZDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>We estimated the risk of incident all-cause hospitalisation\/ED visits and all-cause mortality associated with concurrent BZD use by applying a matched-pair analyses comparing concurrent use to opioid only use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Concurrent BZD use occurred in 17% of opioid users (179\u2009805\/1\u2009056\u2009773). Overall, concurrent use was associated with higher risk of hospitalisation\/ED visit (OR 1.13, p&lt;0.001) and all cause death (OR 1.90; p&lt;0.001). The estimated risk of hospitalisation\/ED visit was highest in those &gt;65 (OR 1.5; p&lt;0.001), using multiple health providers (OR 1.67; p&lt;0.001) and &gt;365 days of opioid use (OR 1.76; p&lt;0.001). Events due to opioid toxicity were also associated with concurrent use (OR 1.8; p&lt;0.001). Opioid dose-response effects among concurrent patients who died were also noted (OR 3.13; p&lt;0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>Concurrent use of opioids and BZDs further contributes to the risk of hospitalisation\/ED visits and mortality in Alberta, Canada over opioid use alone, with higher opioid doses, older age and increased number of unique health providers carrying higher risks. Regulatory bodies and health providers should reinforce safe drug-use practices and be vigilant about coprescribing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-038692","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T16:06:20Z","timestamp":1605888380000},"page":"e038692","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Concurrent use of opioids and benzodiazepines\/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: a case cross-over study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-1183","authenticated-orcid":false,"given":"Vishal","family":"Sharma","sequence":"first","affiliation":[{"name":"School of Public Health, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot H","family":"Simpson","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Samanani","sequence":"additional","affiliation":[{"name":"Okaki Health Intelligence, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Jess","sequence":"additional","affiliation":[{"name":"The College of Physicians & Surgeons of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2197-0463","authenticated-orcid":false,"given":"Dean T","family":"Eurich","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"2025101812095823000_10.11.e038692.1","doi-asserted-by":"crossref","unstructured":"Dowell D . CDC guideline for prescribing opioids for chronic pain, 2016.","DOI":"10.1001\/jama.2016.9242"},{"key":"2025101812095823000_10.11.e038692.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760"},{"key":"2025101812095823000_10.11.e038692.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2698"},{"key":"2025101812095823000_10.11.e038692.4","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170363"},{"key":"2025101812095823000_10.11.e038692.5","unstructured":"ISMP Canada . Essential clinical skills for opioid prescribers, 2017. Available: https:\/\/www.ismp-canada.org\/download\/OpioidStewardship\/Opioid-Prescribing-Skills.pdf [Accessed Nov 2018]."},{"key":"2025101812095823000_10.11.e038692.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.07.004"},{"key":"2025101812095823000_10.11.e038692.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030858"},{"key":"2025101812095823000_10.11.e038692.8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","article-title":"Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014","volume":"51","author":"Hwang","year":"2016","journal-title":"Am J Prev Med"},{"key":"2025101812095823000_10.11.e038692.9","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy264","article-title":"Benzodiazepine and opioid co-usage in the US population, 1999-2014: an exploratory analysis","volume":"42","author":"Vozoris","year":"2019","journal-title":"Sleep"},{"key":"2025101812095823000_10.11.e038692.10","doi-asserted-by":"crossref","unstructured":"Gomes T . Latest trends in opioid-related deaths in Ontario: 1991 to 2015. Ontario Drug Policy Research Network, 2017.","DOI":"10.31027\/ODPRN.2017.01"},{"key":"2025101812095823000_10.11.e038692.11","unstructured":"Manitoba Health . Surveillance of opioid misuse and overdose in Manitoba [online], 2017. Available: https:\/\/www.gov.mb.ca\/health\/publichealth\/surveillance\/docs\/opioid\/2017\/q1_opioid.pdf"},{"key":"2025101812095823000_10.11.e038692.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3207"},{"key":"2025101812095823000_10.11.e038692.13","unstructured":"World Health Organization . International language for drug utilization research, ATC\/DDD, 2020. Available: https:\/\/www.whocc.no\/ [Accessed Jun 2020]."},{"key":"2025101812095823000_10.11.e038692.14","unstructured":"Government of Canada . Drug product database online query, 2020. Available: https:\/\/health-products.canada.ca\/dpd-bdpp\/index-eng.jsp [Accessed June 2020]."},{"key":"2025101812095823000_10.11.e038692.15","unstructured":"College of Physicians and Surgeons of Alberta . TPP Alberta medications list. Triplicate prescription program, 2020. Available: http:\/\/www.cpsa.ca\/tpp\/tpp-medication-list\/ [Accessed Jun 2020]."},{"key":"2025101812095823000_10.11.e038692.16","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200111000-00008"},{"key":"2025101812095823000_10.11.e038692.17","unstructured":"College of Physicians and Surgeons of Alberta . Tpp Alberta \u2013 OME and DDD conversion factors, 2020. Available: http:\/\/www.cpsa.ca\/tpp\/ [Accessed Jun 2020]."},{"key":"2025101812095823000_10.11.e038692.18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.21.1.193"},{"key":"2025101812095823000_10.11.e038692.19","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12186"},{"key":"2025101812095823000_10.11.e038692.20","unstructured":"Schneeweiss S , Sturmer T , Maclure M . Case crossover and case-time-control design. Pharmacoepi & drug safety 1997, 1997."},{"key":"2025101812095823000_10.11.e038692.21","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.100702"},{"key":"2025101812095823000_10.11.e038692.22","first-page":"686","article-title":"And drug-related mortality in patients with nonmalignant PainOpioid dose and drug-related mortality","volume":"171","author":"Gomes","year":"2011","journal-title":"JAMA Internal Medicine"},{"key":"2025101812095823000_10.11.e038692.23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3109\/10826084.2013.796989","article-title":"Substance use and other mental health disorders among Veterans returning to the inner city: prevalence, correlates, and rates of unmet treatment need","volume":"48","author":"Vazan","year":"2013","journal-title":"Subst Use Misuse"},{"key":"2025101812095823000_10.11.e038692.24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ajad.12319","article-title":"The epidemiology of substance use disorders in US veterans: a systematic review and analysis of assessment methods","volume":"25","author":"Lan","year":"2016","journal-title":"Am J Addict"},{"key":"2025101812095823000_10.11.e038692.25","doi-asserted-by":"publisher","DOI":"10.1037\/1541-1559.4.3.149"},{"key":"2025101812095823000_10.11.e038692.26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0919","article-title":"Exposure-Response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries","volume":"1","author":"Hernandez","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025101812095823000_10.11.e038692.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00449.x"},{"key":"2025101812095823000_10.11.e038692.28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.24095\/hpcdp.38.9.02","article-title":"At-a-glance - Opioid surveillance: monitoring and responding to the evolving crisis","volume":"38","author":"Abdesselam","year":"2018","journal-title":"Health Promot Chronic Dis Prev Can"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-038692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:10:08Z","timestamp":1760814608000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-038692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,20]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-038692"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-038692","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}